Roche’s vouchers to patients breach regulatory codeBMJ 2009; 338 doi: https://doi.org/10.1136/bmj.b899 (Published 03 March 2009) Cite this as: BMJ 2009;338:b899
- Roger Dobson
The pharmaceutical giant Roche has breached the British drug industry’s code of conduct with a scheme that provided shopping vouchers to young patients as an incentive to use one of the company’s products.
The scheme was described as “unacceptable” by the code of conduct panel of the Association of the British Pharmaceutical Industry, which found that Roche breached the code of practice in an adherence and incentive scheme for its cystic fibrosis drug dornase alfa (marketed as Pulmozyme).
“The panel was very concerned about a pharmaceutical company in effect providing cash as an incentive to patients to use its medicine,” says a report on the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial